Evidence map›Paper›PMID 33927773›Full record

ArticleInternational journal of pediatrics2021

Propranolol for Treatment of Infantile Hemangioma: Efficacy and Effect on Pediatric Growth and Development.

Rachel A Giese, Merit Turner, Mario Cleves, J Reed Gardner, Gresham T Richter

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Propranolol in the Treatment of Infantile Hemangiomas.Clinical, cosmetic and investigational dermatology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Rachel A GieseDepartment of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Texas Rio Grande Valley School of Medicine, 1201 W University Dr, Edinburg, TX, Canada 78539.ORCID https://orcid.org/0000-0003-2234-7649
Merit TurnerDepartment of Otolaryngology-Head and Neck Surgery, University of Arkansas of the Medical Sciences, 4301 W, St Little Rock, Markham, AR, Canada 72205.ORCID https://orcid.org/0000-0001-9273-5415
Mario ClevesMorsani College of Medicine, Department of Pediatrics, Health Informatics Institute, University of South Florida, 3650 Spectrum Blvd, Tampa, FL 33612, USA.
J Reed GardnerDepartment of Otolaryngology-Head and Neck Surgery, University of Arkansas of the Medical Sciences, 4301 W, St Little Rock, Markham, AR, Canada 72205.ORCID https://orcid.org/0000-0002-5421-718X
Gresham T RichterDepartment of Otolaryngology-Head and Neck Surgery, University of Arkansas of the Medical Sciences, 4301 W, St Little Rock, Markham, AR, Canada 72205.ORCID https://orcid.org/0000-0003-3423-1213
University of Arkansas for Medical Sciences · USThe University of Texas Rio Grande Valley · USUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePropranolol has been successful in treating problematic infantile hemangiomas (IH) but concerns regarding its effect on normal growth and development have been raised. This study examines physical growth, developmental milestones, and human growth hormone (hGH) levels in infants receiving propranolol for problematic IH.

methodMonthly heights and weights of children undergoing propranolol therapy for IH were prospectively collected and tabulated. Data analysis and comparison to World Health Organization (WHO) weight-for-age and weight-to-length

resultsA total of 185 children receiving propranolol therapy between 2008 and 2013 for IH were assigned to this study. The children were divided into two cohorts based on the presence of comorbidities or risk factors that may affect growth and development (

conclusionPropranolol therapy is effective and well tolerated in the treatment of infantile hemangiomas. This study suggests that propranolol does not impair growth and has no impact on normal pediatric development.

Identifiers

PMID33927773
PMCPMC8049833
OpenAlexW3153696591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.